Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory Mediators

Table 1

Characteristics of patients enrolled in the study.

Patient	Age	Sex	BMI		HgbA1C (n.v. 6,6)		HOMA		Waist circum (cm)		Diabetes treatment: drugs (+diet and physical activity)	Lenght of treatment (years/months)	Comorbidties
			Before	After	Before	After	Before	After	Before	After
1	51	M	35	34	8.5	7.2	2.9	3.6	136	112	Gliclazid	0/3	HTN, DL
2	66	M	30	30	15.6	6.0	6.0	6.0	104	100	Repaglinid	0/6	HTN, DL
3	52	F	31	31	7.9	6.3	7.3	6.9	98	89	Metformin	0/6	HTN, DL
4	67	F	36	35	7.3	6.7	5.0	5.2	113	105	Metformin	1/2	HTN, DL, CVA
5	64	M	28	24	7.3	5.6	1.3	0.9	104	93	Metformin	0/6	HTN, DL
6	65	F	27.5	25.5	9.5	6.7	5.1	1.9	113	104	Metformin	1/0	HTN, DL
7	67	M	31	27	7.9	5.8	4.8	2.3	107	96	Metformin	0/5	HTN, DL
8	60	M	31	30	9.4	7.2	5.6	3.9	103	96	Metformin	0/2	HTN, DL
9	74	F	37	33	7.7	6.6	3.2	1.8	124	107	Metformin + Repaglinid	1/2	HTN, DL, Afib
10	67	F	38	34	8.4	6.4	8.7	2.5	136	128	Metformin + Glimepirid	0/6	HTN, DL
11	50	M	29	27	12.0	6.9	3.8	1.6	96	106	Metformin + Glimepirid	0/6	HTN, DL
12	71	F	40	38	8.4	6.5	5.6	3.9	133	127	Metformin	0/8	HTN, DL
13	71	F	43	39	8.2	6.7	5.7	2.6	109	109	Metformin	0/5	HTN, DL
14	73	F	32	29	8	6.9	4.5	3.8	102	102	Metformin	0/8	HTN, DL
15	59	F	41	40	9.1	6.7	10.9	4.0	121	118	Metformin	1/5	HTN, DL
16	55	F	41	39	8.4	6.9	6.0	2.3	123	102	Metformin	0/2	HTN, DL
17	47	M	31	29	8.8	6.6	9.5	3.5	104	96	Metformin	1/9	HTN, DL

Pat: patient; n.v: normal value; circum: circumference; treatment: Treatment; comorbidities: cardiovascular comorbidities; HTN: hypertension; DL: dyslipidemia; CVA: cerebral vascular accident; Afib: atrial fibrillation.